Literature DB >> 8890727

Determination of free follistatin levels in sera of normal subjects and patients with various diseases.

Y Sakamoto1, Y Shintani, K Harada, M Abe, K Shitsukawa, S Saito.   

Abstract

We developed an assay system for measuring free follistatin by using an anti-follistatin mouse monoclonal antibody and [125I]activin A. The sensitivity of this assay was 0.5 microgram/l and cross-reactivities with inhibin, luteinizing hormone, follicle-stimulating hormone and growth hormone were all less than 0.5%. The dose-response curves of human sera and follicular fluid were parallel to the standard curve, and the follicular fluid contained a large amount of follistatin (6.4 +/- 0.5 mg/l, mean +/- SEM; N = 13). The within- and between-assay coefficients of variation calculated from the analysis of serum samples of four different concentrations were 3.3-7.8% and 3.9-11.0%, respectively. The recovery rates of free follistatin at five different doses were 86.4 - 102.4%. When activin A was added to the same sample, free follistatin recovery rate declined dose-dependently. Gel filtration analyses of human serum and follicular fluid resulted in a single peak corresponding to authentic follistatin. Using this assay, free follistatin concentrations in sera were measured in normal, pregnant and diseased subjects. The free follistatin level in serum of normal adults was 3.5 +/- 0.2 micrograms/l (N = 60), which was significantly elevated in pregnant women (16.7 +/- 1.3 micrograms/l, N = 56), and in patients with chronic liver disease (8.1 +/- 1.1 micrograms/l, N = 20), chronic renal failure (6.7 +/- 0.9 micrograms/l, N = 42), advanced solid cancer (8.5 +/- 1.0 micrograms/l, N = 39) and hematological malignancies (6.8 +/- 1.0 micrograms/l, N = 18). These data indicated that the free follistatin concentration in serum is detectable and varies during pregnancy and in various diseased states.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890727     DOI: 10.1530/eje.0.1350345

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival.

Authors:  Tetsu Miyamoto; Juan Jesús Carrero; Abdul Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2011-02-24       Impact factor: 8.237

2.  Elevated circulating follistatin associates with an increased risk of type 2 diabetes.

Authors:  Chuanyan Wu; Yan Borné; Rui Gao; Maykel López Rodriguez; William C Roell; Jonathan M Wilson; Ajit Regmi; Cheng Luan; Dina Mansour Aly; Andreas Peter; Jürgen Machann; Harald Staiger; Andreas Fritsche; Andreas L Birkenfeld; Rongya Tao; Robert Wagner; Mickaël Canouil; Mun-Gwan Hong; Jochen M Schwenk; Emma Ahlqvist; Minna U Kaikkonen; Peter Nilsson; Angela C Shore; Faisel Khan; Andrea Natali; Olle Melander; Marju Orho-Melander; Jan Nilsson; Hans-Ulrich Häring; Erik Renström; Claes B Wollheim; Gunnar Engström; Jianping Weng; Ewan R Pearson; Paul W Franks; Morris F White; Kevin L Duffin; Allan Arthur Vaag; Markku Laakso; Norbert Stefan; Leif Groop; Yang De Marinis
Journal:  Nat Commun       Date:  2021-11-10       Impact factor: 14.919

3.  Identification and characterization of stem cell secretome-based recombinant proteins for wound healing applications.

Authors:  Ji Hyun Kim; Denethia S Green; Young Min Ju; Mollie Harrison; J William Vaughan; Anthony Atala; Sang Jin Lee; John D Jackson; Cory Nykiforuk; James J Yoo
Journal:  Front Bioeng Biotechnol       Date:  2022-07-22

4.  Serum Levels of Follistatin Are Positively Associated With Serum-Free Thyroxine Levels in Patients With Hyperthyroidism or Euthyroidism.

Authors:  Fen-Yu Tseng; Yen-Ting Chen; Yu-Chao Chi; Pei-Lung Chen; Wei-Shiung Yang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

5.  Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes.

Authors:  Tang Cam Phung Pham; Kirstine Nyvold Bojsen-Møller; Sten Madsbad; Jørgen Frank Pind Wojtaszewski; Erik Arne Richter; Lykke Sylow
Journal:  Int J Obes (Lond)       Date:  2020-09-01       Impact factor: 5.095

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.